Litcius/Paper detail

Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions

Melissa Rosenthal, Charles Stoecker, Andrew J. Leidner, Bo‐Hyun Cho, Tamara Pilishvili, Miwako Kobayashi

2024Vaccine11 citationsDOI

Topics & Concepts

Pneumococcal conjugate vaccineMedicinePneumococcal diseasePediatricsConjugateStreptococcus pneumoniaeVirologyMicrobiologyBiologyAntibioticsMathematical analysisMathematicsPneumonia and Respiratory InfectionsRespiratory viral infections researchAdvanced Causal Inference Techniques
Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions | Litcius